SBIR/STTR Research Award

Wireless, implantable optofluidic systems for programmed pharmacology and optogenetics

Award identifier 2a5dac2145f9a426e4d84d5fc2a28239a786492d96bdd8b293fcb058928b62abAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,358,146

Program and phase

STTR · Phase II

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Neurolux, Inc.
Proposal award date
2019-05-01
Contract end date
2021-04-30
UEI
J5AJLKL8SCC4
Solicitation number
PA18-575
Topic code
101

Research abstract

Project Summary/Abstract Neuroscience research over the last decade has been revolutionized by many technological advancements. Pharmacology and optogenetics represent two distinct, and sometimes complementary tools used in neuroscience research to study the central and peripheral nervous systems in the context of the BRAIN initiative. Advanced interrogations of underlying neural circuits and biology are often frustrated, however, by technological limitations that prevent the use of these approaches to study natural behaviors of untethered, freely moving animals. Traditional fiber-optic cable for optogenetics and bulky metal cannulas connected with external mechanical pumps for pharmacology impart significant damage to fragile neural tissue, limit the natural behavior of freely moving animals, affect social interactions and movements in complex, naturalistic 3D environment, and lead to persistent irritation at the biotic/abiotic interface due to mechanical mismatch and micromotions. These drawbacks, together with the costly setup, of current technologies motivate the development of innovative engineering designs to improve fidelity, operational ease, versatility and range of advanced brain research studies with live animal models. Our work during Phase I developed an integrated, wireless platform that combines capabilities in programmable pharmacology via soft μ-fluidic channels and optogenetics through an implantable μ-scale inorganic light emitting diodes (μ-ILEDs). The proposed work for Phase II focuses on translational engineering research to refine the device designs and to develop a low-cost, mass-manufacturing process. Specifically, the proposed work will (1) establish device designs, and manufacturing process for low-cost, outsourced production, (2) expand the functionality for directly interfacing with peripheral nerve and spinal cord, and (3) develop advanced capabilities in power harvesting, modulation, and control, and broaden the impact on neuroscience research. This work will yield a broadly useful, low-cost, wireless platforms for programmable pharmacology and optogenetics in various contexts of essential relevance to the BRAIN initiative.Project Narrative The goal of this project is to advance novel classes of soft, flexible device technologies that will allow for the delivery of pharmacological agents to precisely targeted regions of the deep brain. It will also advance capabilities in advanced, wireless, optoelectronic systems for optogenetics, and combined with the pharmacological platforms listed above, will extend experimental possibilities in neuroscience research beyond the brain, and to the spinal cord and peripheral nervous system. Over the course of this project, we will develop and deploy novel manufacturing schemes that will allow for low-cost production of these platforms, to effectively distribute them to the neuroscience community.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

10 SBIR/STTR records share this UEI (2017–2025). Reported award amounts total $10,900,870. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.